基于受体的替代亚型与乳腺癌内在亚型的不一致:对影像生物标志物开发的启示
该研究基于17个公共乳腺癌数据集的3050例患者,分析免疫组化标志物(雌激素受体/孕激素受体/人表皮生长因子受体2)替代分型与分子内在分型(基底样、HER2富集、管腔A或B)的一致性和准确性,发现三受体状态与内在分子亚型一致性差,反对将其用于预后基因组影像生物标志物的设计。
要点
- 基于免疫组化亚型的 intrinsic 亚型准确率:管腔A 71.7%、管腔B 53.7%、HER2富集64.8%、基底样81.7%。
- 一致性κ值:管腔A和HER2富集为fair(κ=0.36),基底样为good(κ=0.65),管腔B为poor(κ=0.09)。
- 模拟显示影像误分类会降低影像真亚型准确率和κ值,并缩小管腔A与基底样亚型间的生存差异。
核心结论
- 三受体状态与乳腺癌内在分子亚型一致性差,反对将其用于预后基因组影像生物标志物的设计。
研究设计与样本
- 回顾性分析17个公共乳腺癌数据集的3050例患者,包含免疫组化受体状态和分子分型,计算诊断准确性和κ一致性,并进行模拟评估影像标志物预测分子分型及误分类对生存的影响。
诊断标准与关键数值
- 基于免疫组化亚型的 intrinsic 亚型准确率:管腔A 71.7%、管腔B 53.7%、HER2富集64.8%、基底样81.7%。
- 一致性κ值:管腔A和HER2富集为fair(κ=0.36),基底样为good(κ=0.65),管腔B为poor(κ=0.09)。
- 模拟显示影像误分类降低影像真亚型准确率和κ值,并缩小管腔A与基底样亚型间的生存差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine the concordance and accuracy of imaging surrogates of immunohistochemical (IHC) markers and the molecular classification of breast cancer. Materials and Methods A total of 3050 patients from 17 public breast cancer data sets containing IHC marker receptor status (estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 [HER2]) and their molecular classification (basal-like, HER2-enriched, luminal A or B) were analyzed. Diagnostic accuracy and concordance as measured with the κ statistic were calculated between the IHC and molecular classifications. Simulations were performed to assess the relationship between accuracy of imaging-based IHC markers to predict molecular classification. A simulation was performed to examine effects of misclassification of molecular type on patient survival. Results Accuracies of intrinsic subtypes based on IHC subtype were 71.7% (luminal A), 53.7% (luminal B), 64.8% (HER2-enriched), and 81.7% (basal-like). The κ agreement was fair (κ = 0.36) for luminal A and HER2-enriched subtypes, good (κ = 0.65) for the basal-like subtype, and poor (κ = 0.09) for the luminal B subtypes. Introduction of image misclassification by simulation lowered image-true subtype accuracies and κ values. Simulation analysis showed that misclassification caused survival differences between luminal A and basal-like subtypes to decrease. Conclusion There is poor concordance between triple-receptor status and intrinsic molecular subtype in breast cancer, arguing against their use in the design of prognostic genomic-based image biomarkers. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Jamshidi N, Yamamoto S, Gornbein J, et al. Receptor-based Surrogate Subtypes and Discrepancies with Breast Cancer Intrinsic Subtypes: Implications for Image Biomarker Development. Radiology. 2018. PMID: 30040052. doi:10.1148/radiol.2018171118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。